Altimmune Inc. (ALT) and Assembly Biosciences Inc. (NASDAQ:ASMB) Comparison side by side

As Biotechnology companies, Altimmune Inc. (NASDAQ:ALT) and Assembly Biosciences Inc. (NASDAQ:ASMB) are our subject to contrast. And more specifically their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Altimmune Inc. 3 3.30 N/A -15.41 0.00
Assembly Biosciences Inc. 15 24.21 N/A -4.25 0.00

Table 1 highlights Altimmune Inc. and Assembly Biosciences Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents Altimmune Inc. (NASDAQ:ALT) and Assembly Biosciences Inc. (NASDAQ:ASMB)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Altimmune Inc. 0.00% -87.3% -71%
Assembly Biosciences Inc. 0.00% -56.5% -42.6%

Volatility & Risk

Altimmune Inc.’s volatility measures that it’s 205.00% more volatile than S&P 500 due to its 3.05 beta. Assembly Biosciences Inc.’s 41.00% more volatile than S&P 500 which is a result of the 1.41 beta.


The Current Ratio and Quick Ratio of Altimmune Inc. are 13.4 and 13.4 respectively. Its competitor Assembly Biosciences Inc.’s Current Ratio is 8 and its Quick Ratio is 8. Altimmune Inc. can pay off short and long-term obligations better than Assembly Biosciences Inc.

Institutional & Insider Ownership

Institutional investors owned 9.4% of Altimmune Inc. shares and 89% of Assembly Biosciences Inc. shares. Insiders owned roughly 14.29% of Altimmune Inc.’s shares. On the other hand, insiders owned about 6.3% of Assembly Biosciences Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Altimmune Inc. 3% 0.84% -16.67% -27.71% -78.38% 16.5%
Assembly Biosciences Inc. -4.36% -15.6% -18.51% -43.16% -69.75% -44.74%

For the past year Altimmune Inc. had bullish trend while Assembly Biosciences Inc. had bearish trend.


On 5 of the 7 factors Assembly Biosciences Inc. beats Altimmune Inc.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.